Editorial: Bone metastases by Valenti, Maria Teresa et al.
Frontiers in Oncology | www.frontiersin.org
Edited and reviewed by:
Tao Liu,






This article was submitted to
Molecular and Cellular Oncology,
a section of the journal
Frontiers in Oncology
Received: 14 July 2021
Accepted: 16 July 2021
Published: 30 July 2021
Citation:
Valenti MT, Mottes M,
Dalle Carbonare L and Feron O




published: 30 July 2021
doi: 10.3389/fonc.2021.741515Editorial: Bone Metastases
Maria Teresa Valenti 1*, Monica Mottes2, Luca Dalle Carbonare1 and Olivier Feron3
1 Department of Medicine, University of Verona and Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy,
2 Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy, 3 Pole of
Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain,
Brussels, Belgium
Keywords: bone, osteoblasts, osteoclasts, endosteal niche, metastatic niche
Editorial on the Research Topic
Bone Metastases
Solid tumors often metastasize into bones affecting quality of life and overall survival of cancer
patients. Despite improvement of diagnostic tools, the presence of bone metastases often reveals an
advanced disease stage with a median survival of a few months and limited appropriate therapies.
Moreover, patients with bone metastases suffer from considerable morbidity including pain,
fractures and hypercalcemia (1). Bone metastases are often detected in patients with breast,
prostate and lung cancers but it is also increasingly recognized that the ability of other types of
cancer to form bone lesions has been underestimated for many decades.
Metastasization is a multi-step process where cancer cells escape from the primary tumor,
intravasate, survive in the bloodstream and later extravasate from the circulation to develop at a
distant site; lymphatics represent another route for migrating cancer cells that will first colonize
nodes and later on potentially reach the circulation. Adaptation to the new environment is a pre-
requisite for effective growth in conditions different from the primary site. Bone metastases result
from complex interactions of cancer cells with hematopoietic stem cells, endothelial cells as well as
bone cells (osteoblasts with bone forming activity and osteoclasts with bone resorption activity). In
the last years, the contribution of osteoclasts to bone metastasization has been largely investigated
including through the dissection of their crosstalk with cancer cells (2). The latter were for instance
documented to play a central role in destroying bone upon lowering of extracellular pH, a
prerequisite for osteoclast activity (3, 4). Other studies have revealed that cancer cells interact
with bone cells either to modulate their dormancy or promote drug resistance (5, 6).
This Research Topic includes two reviews that paint a very broad picture of how the interplay
between tumor and bone-resident cells drives the local development of metastases. While Gyori and
Moscai review the different osteoclast signaling pathways that are related to the pathological bone
loss, Haider et al. describe the interaction between tumor cells and endosteal niche cells during the
early stages of breast cancer bone metastasis, with a particular focus on mesenchymal-derived
osteoblasts and fibroblasts. The role of calcium, an important building block of bones but also a
recognized actor in the development of bone metastases is also addressed in this RT. Through the
review of major calcium channels and/or calcium-related routes (ie, TRPs, VGCCs, SOCE, and
P2Xs), Yang et al. provide evidence that alterations in calcium homeostasis in bone metastases
directly participate in tumor progression. Das et al. also examine the role of calcium by focusing on
the Ca2+-sensing receptor (CaSR), a dimeric class-C G protein-coupled receptor (GPCR). In their
review, these authors explore the hypothesis of CaSR acting as an oncogene in breast cancer andJuly 2021 | Volume 11 | Article 7415151
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osteolysis promotes tumor growth and inversely.
Several articles within this RT explore recent developments in
the search for therapeutic strategies targeting bone metastases.
Kratzsch et al. describe how mTOR inhibitor everolimus but also
axitinib, a specific VEGF receptor tyrosine kinase inhibitor,
may prevent and retard formation of symptomatic spinal
metastases. Interestingly, La Manna et al. who used patient-
derived organoids and xenografts (PDX) models from bone-
metastatic prostate cancer report the therapeutic benefit of
mTORC1/2 inhibitor Rapalink-1, further supporting a role of
mTOR pathway in cancers metastasizing in bones. Besides the
above anti-oncogenic approaches, targeting metabolism
represents another option which may take advantage of the
emerging development of new drugs in this field. Tiedemann
et al. examine current evidence underlying how altered
metabolism in cancer cells may impact on substrate availability
for bone cells, and on consecutive alterations in osteoclast
differentiation and activity. Xu et al. follow a more focused
approach examining how a component of the electron
transport chain complex I (ie, NDUFA4L2) accounts for
epithelial-to-mesenchymal transition of osteosarcoma cells,
pointing out OXPHOS as a critical metabolic path in theFrontiers in Oncology | www.frontiersin.org 2development of primary malignant bone tumors. Finally, Xu
et al. discuss recent progress on evaluating the role of
endoplasmic reticulum stress on bone metastases, identifying a
set of potential targets to develop new therapeutic modalities
directed against bone metastases. Besides therapeutic
approaches, this RT also emphasizes the obvious interest to
identify patients at risk for bone metastases in order to treat
them at an earlier stage and thereby improve clinical outcomes;
current studies evaluating such prognostic biomarkers are
summarized by Iuliani et al.
Altogether, the different contributions to this RT offer a series
of insightful sets of data to better understand mechanisms
involved in the multi-cellular process driving bone metastases
and open new perspectives of treatment to counteract the onset
of this major life-threatening cancer complication.AUTHOR CONTRIBUTIONS
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